FDA
-
-
-
-
-
-
-
Traws Pharma secures $60 million financing led by Sirenia Capital
-
-
-
-
-
-
-
Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients
-
-
-
-
-
-
-
Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025
-
-
-
-
-
-
-
Traws Pharma Reports Full Year 2024 Results and Business Highlights
-
-
-
-
-
-
-
Traws Pharma’s Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR
-
-
-
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

